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Aims: To evaluate short- and long-term glycaemic control and hypoglycaemia incidence in
insulin-naïve patients ≥30 years of age with type 2 diabetes (T2DM) initiating basal insulin (BI)
with or without oral anti-hyperglycaemic drugs (OADs).
Methods: This was an observational, retrospective longitudinal analysis of electronic medical
records from 5 European countries and the USA. A multivariable logistic regression model
assessed baseline and short-term (0-3 months post BI initiation) factors associated with long-
term (3-24 months) glycaemic control and hypoglycaemia.
Results: Overall, 40 627 patients were included; 20.9% and 27.8% achieved the general HbA1c
target of ≤7% at 3 and 24 months post BI initiation, respectively. Failure to achieve HbA1c
≤7% at 3 months was associated with increased risk of failing to achieve target at 24 months
(odds ratio [OR], 3.70 [95% CI, 3.41-4.00]). Over 24 months, 8.9% of patients experienced a
recorded hypoglycaemic event. Hypoglycaemia during the initial 3-month period was associ-
ated with longer-term risk of these events over the ensuing 3 to 24 months (OR, 5.71 [95% CI,
4.67-6.99]).
Conclusions: Initiating BI with or without OADs is associated with short- and long-term subopti-
mal glycaemic control; the majority of patients fail to achieve HbA1c target ≤7% in the first
3 months, or after 2 years of BI treatment. Treatment response and hypoglycaemia incidence by
3 months post BI initiation are associated with longer-term glycaemic control and hypoglycaemic
risk, respectively. These results support the need for early anti-hyperglycaemic interventions that
more effectively control blood glucose levels without increasing the risk of hypoglycaemia.
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1 | INTRODUCTION
The overarching goal of diabetes management is to reduce the risk of
acute and chronic complications associated with the disease, in part,
through appropriate glycaemic control.1,2 The American Diabetes
Association (ADA) and European Association for the Study of
Diabetes (EASD) jointly recommend an evidence-based general target
glycated haemoglobin (HbA1c) level of ≤7.0% (≤53 mmol/mol) for
people with type 2 diabetes (T2DM); this target should be further
individualized, to be more or less intensive according to individual
patient profiles (eg, age, comorbidities, hypoglycaemia risk) and
preferences.1,3–7 The ADA-EASD position statement also recom-
mends optimization of therapy if glycaemic targets are not achieved
after 3 months.1†At the time of the study.
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Effective diabetes therapy requires a delicate balance between
the benefits of strict glycaemic control and the risk of hypoglycaemia
and other drug-related side effects.8 Indeed, many physicians cite
hypoglycaemia as a critical barrier to insulin therapy initiation and
adherence.9–11 Hypoglycaemia, or fear of such episodes, is also
known to contribute to patients missing, mis-timing or reducing insu-
lin doses,12 which may compromise glycaemic control. Despite com-
prehensive treatment recommendations, many patients experience
years of inadequate glycaemic control because of delays in treatment
intensification (so-called inertia), especially when transition to insulin
treatment is needed.13 Once insulin therapy has been initiated, many
patients still struggle to achieve or maintain glycaemic targets.14 This
is a concern, given the increased risk of complications such as cardio-
vascular events in patients with poor glycaemic control and delayed
treatment intensification.15
Therefore, despite a wide range of available treatment options,
and advancements in insulin therapies offering an improved benefit/
risk profile, lowering blood glucose without increasing the risk of
hypoglycaemia in insulin-treated patients remains a clinical challenge.
In order to evaluate the extent of unmet medical needs of patients
with T2DM initiating basal insulin (BI) in terms of glycaemic control
and hypoglycaemia incidence, we conducted an analysis of an elec-
tronic medical records (EMRs) database in 5 European countries
(France, Germany, Italy, Spain and the UK) and the USA. The focus of
the investigation was to identify patient characteristics in the first
3 months of BI initiation that may predict longer (24-month) achieve-
ment of glycaemic control and risk of hypoglycaemia.
2 | METHODS
2.1 | Study design
This was an observational, retrospective, longitudinal analysis of the
Cegedim Strategic Data (CSD) patient database of general
practitioner EMRs. CSD longitudinal patient databases collect daily,
non-interventional, anonymized patient-level data from practice man-
agement software used during physician office visits worldwide; we
utilized data from France, Germany, Italy, Spain, the UK and the USA
in our analyses.
Patients (N = 40 627) initiating BI with or without oral anti-
hyperglycaemic drugs (OADs)/glucagon-like peptide-1 receptor ago-
nists (GLP1-RA) from January 1, 2008 to September 30, 2012 were
included in the analysis if they had a diagnosis of T2DM, were aged
≥30 years at time of diagnosis, had no prior use of insulin and had used
OADs at some time prior to initiating BI. Patients were excluded if they
were receiving rapid-acting or premix insulin prior to BI initiation, but
use of prandial insulin was permitted in the post-index period.
Patients initiating BI treatment were identified from a first pre-
scription for BI (defined as the index date). Patients had to have
≥1 HbA1c measurement within 12 months pre-index and ≥1 HbA1c
measurement within 24 months post BI initiation, as well as data
available for ≥1 year before and ≥2 years after the index date.
The 1-year pre-index period was used to ascertain patient char-
acteristics and medical and medication history. Comorbidities were
assessed as recorded in the EMR, which relied on a patient receiving
either a primary or secondary recorded diagnosis during an office
visit. The International Classification of Diseases 9th Edition (ICD-9)
was used for disease classification in Italy and the USA, and the Inter-
national Classification of Diseases 10th Edition (ICD-10) was used in
Germany. In Spain, in-country classification systems were mapped to
ICD-10. In France, in-country classification systems were mapped to
ICD-10 and to the International Classification of Primary Care 2nd
Edition (ICPC-2). Disease classification was based on Read codes in
the UK.16 Glycaemic control, hypoglycaemia incidence and medica-
tion use were evaluated during 2 years following the index date post
BI initiation.
2.2 | Outcomes
Glycaemic control was determined according to measured levels of
HbA1c at the index date and at 3, 6, 12 and 24 months post index.
Target achievement was defined as the proportion of patients achiev-
ing a threshold HbA1c value of ≤7.0% (≤53 mmol/mol). The propor-
tion of patients experiencing hypoglycaemia was recorded at 3, 6,
12 and 24 months post index. As this was a real-world, international
study, no single standardized definition of hypoglycaemia could be
used. While we expect that most clinicians used the ADA/EASD defi-
nition of hypoglycaemia, some clinicians may have used local/national
guidelines alternatively to identify such events. Hypoglycaemic epi-
sodes were captured as a recorded diagnosis of any hypoglycaemia
or fasting plasma glucose (FPG) of ≤3.9 mmol/L (≤70 mg/dL) during
an office visit.17
2.3 | Data analysis and statistics
We examined potential pre-defined factors associated with long-term
(3-24 months) glycaemic control and hypoglycaemia burden, based
on patient characteristics, short-term (0-3 months) glycaemic
response and hypoglycaemia experienced during the first 3 months
of BI treatment. Patient characteristics included age, gender, body
mass index (BMI), microvascular (nephropathy, retinopathy and neu-
ropathy) and macrovascular comorbidities (myocardial infarction, con-
gestive heart failure, ischemic stroke and peripheral vascular disease),
pre-index HbA1c, history of hypoglycaemia and other general comor-
bidities (hypertension, mental illness, dementia, chronic kidney dis-
ease [CKD]). The association between each of these factors and long-
term response was first evaluated in a univariate logistic regression
analysis. The final multivariable regression model included covariates
with a P value ≤0.1 identified from the univariate logistic regression
analysis. The overall effect across all 6 countries was derived from a
meta-analysis using an inverse-variance weighted method.
3 | RESULTS
3.1 | Study population at index date
A total of 40 627 patients were included in the analysis, with the
number of patients from each country ranging from 1117 (Spain) to
30 220 (USA). Patient characteristics are shown in Table 1. In Europe,
1156 MAURICIO ET AL.
over half of the patients were older adults (>65 years of age). In the
USA, the proportion of older patients was lower, with a population
median age of 62 years.
The prevalence of comorbid conditions reported in the database var-
ied rather widely among countries (Table 1). The prevalence of reported
microvascular comorbidities was highest in the UK (25.2% of patients),
while this ranged from 5.0% (Spain) to 17.5% (USA) in the other 5 coun-
tries. The proportion of patients with reported macrovascular comorbid-
ities was lowest in the USA (11.7%) and highest in Germany (27.5%).
Renal disease prevalence ranged from 2.6% in France to 30.8% in the UK.
3.2 | Glycaemic control
3.2.1 | Glycaemic control prior to BI initiation
While poor glycaemic control is to be expected in patients initiating
BI, almost half of the patients in France, Italy and Spain, and 62.9% of
patients in the UK, initiated BI with very high HbA1c levels (>9.0%
[>75 mmol/mol]); proportions of patients with HbA1c values in this
category were lower in Germany and the USA (29.8% and 39.5%,
respectively) (Table 1). Mean HbA1c upon BI initiation ranged from
8.5% (69 mmol/mol; Germany) to 9.9% (85 mmol/mol; UK) (Table 1).
3.2.2 | Glycaemic control post BI initiation
Across all countries, mean HbA1c showed the steepest decline during
the first 3 months post index date, continued to decline until
6 months post BI initiation, and then remained stable to the end of
the 24-month post-index period (Figure 1A). The proportion of
patients across all countries achieving HbA1c values ≤7.0%
(53 mmol/mol) increased from 13.5% at index date to 20.9% and
27.8% at 3 and 24 months after BI initiation, respectively. Target
achievement varied among countries, from 8.1% to 28.0% at
3 months, and 17.3% to 33.4% at 24 months post index (Figure 1B).
Compared with patients who achieved an HbA1c target ≤7.0%
[≤53 mmol/mol] 3 months after BI initiation, those with suboptimal gly-
caemic control (HbA1c >7.0% [>53 mmol/mol]) at this time point were
more likely to fail in reaching this target at 24 months (odds ratio [OR],
3.70 [95% confidence interval (CI), 3.41-4.00]) (Figure 2A). Other factors
associated with suboptimal long-term glycaemic control were not con-
sistently identified among countries (Figure S1A). Hypoglycaemia experi-
ence in the pre-index period or in the first 3 months post index was not
associated with failure to achieve glycaemic targets in any country.
3.3 | Hypoglycaemia
3.3.1 | Hypoglycaemia prior to BI initiation
Hypoglycaemia prevalence during the pre-index period varied widely
among countries, from 1.9% of patients in Spain to 9.0% in France
(Table 1).
3.3.2 | Hypoglycaemia post BI initiation
Hypoglycaemia incidence increased post BI initiation compared with
the pre-index period in Germany, Italy, Spain and the USA, but
declined in France and the UK (Figure 3). During the first year after
the index date, 5.1% of patients experienced a hypoglycaemic event
that was recorded in the database; this increased to 8.9% of patients
after 24 months (Figure 3).
TABLE 1 Country-specific patient characteristics at index date
France Germany Italy Spain UK USA Total
N = 2264 N = 2330 N = 1228 N = 1117 N = 3468 N = 30 220 N = 40 627
General
Age, years
Mean (SD) 66.5 (11.8) 67.5 (11.1) 69.1 (11.8) 66.9 (12.3) 65.2 (12.0) 62.1 (11.9) 63.3 (8.0)
Median 66 69 70 68 66 62 67
BMI, kg/m2 (mean [SD]) 29.9 (5.9) 31.3 (6.5) 29.5 (5.7) 29.8 (5.5) 31.5 (6.6) 33.7 (6.5) 32.9 (5.7)
HbA1c, % (mean [SD]) 9.0 (1.9) 8.5 (1.7) 9.1 (1.9) 9.2 (1.9) 9.9 (1.9) 8.9 (1.9) 9.0 (3.0)
HbA1c > 7.0%, % 87.3 81.9 87.5 89.4 96.6 85.5 86.5
HbA1c > 6.5%, % 94.5 93.2 95.0 93.6 98.4 93.1 93.7
HbA1c > 9.0%, % 43.4 29.8 43.8 47.4 62.9 39.5 41.5
Prevalence of comorbidities, %
Hypoglycaemia 9.0 2.4 7.7 1.9 5.1 3.3 3.8
Microvascular comorbiditiesa 5.9 14.4 7.7 5.0 25.2 17.5 16.7
Macrovascular comorbiditiesb 18.9 27.5 15.0 20.1 21.6 11.7 14.2
Myocardial infarction 4.4 5.6 5.4 8.6 7.7 1.7 2.9
Ischaemic stroke 2.4 4.0 0 5.1 5.6 0.3 1.2
Congestive heart failure 4.1 14.5 5.9 4.8 7.5 6.3 6.7
Peripheral vascular disease 10.7 10.3 5.2 5.1 6.5 5.0 5.8
Chronic pulmonary disease 11.5 17.8 15.2 10.8 19.3 12.6 13.4
Renal disease 2.6 8.7 9.3 8.3 30.8 11.0 11.9
Abbreviations: BMI, body mass index; SD, standard deviation.
aMicrovascular comorbidities: nephropathy, retinopathy, and neuropathy.
bMacrovascular comorbidities: myocardial infarction, congestive heart failure, ischaemic stroke and peripheral vascular disease.
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Hypoglycaemia during the initial 3-month period was associated
with longer-term (3-24 months) hypoglycaemia risk (OR, 5.71 [95%
CI, 4.67-6.99]) (Figure 2B). As expected, other well-known factors
associated with long-term risk of hypoglycaemia included comorbid-
ities such as congestive heart failure (OR, 2.40 [95% CI, 1.04-5.55] in
France and 2.18 [95% CI, 1.03-4.63] in the UK) and renal disease
(OR, 1.83 [95% CI, 1.04-3.21) in Germany, 2.61 [95% CI, 1.15-5.92]
in Italy and 1.70 [95% CI, 1.46-1.97] in the USA), but these were not
consistently identified across all countries (Figure S1B).
3.4 | Medication use
3.4.1 | Medication use prior to BI initiation
In the pre-index period, biguanides and sulphonylureas (SUs) were
the most recorded concomitant medications (70.3% and 67.9% of
patients, respectively), while prescriptions of meglitinides, dipeptidyl
peptidase-4 (DPP-4) inhibitors and GLP1-RA were less common
(recorded for 6.3%, 27.6% and 12.3% of patients, respectively)
(Figure 3A and Table S1). DPP-4 inhibitors were prescribed in more
than one-quarter of patients in France, the UK and the USA, but
these prescriptions were only recorded in a small proportion of
patients in Italy (4.4%). Thiazolidinediones and GLP1-RA were most
commonly prescribed in the UK and USA. Conversely, meglitinide
prescriptions were lowest in the UK and USA, and highest in Italy.
3.4.2 | Medication use post BI initiation
There was a decline in OAD/GLP1-RA prescriptions during the 12-
month post-index period compared with the pre-index period
(Figure 4A and Table S1). The exception to this was a small rise in the
proportion of patients receiving meglitinide treatment in Italy (increas-
ing from 32.7% of patients pre-index to 34.4% post index). Substantial
reductions in the proportion of patients treated with SU were
observed in all countries post index; however, SU use still remained
high in the post-index period (55.1%), particularly in the UK and USA.
The majority of patients (88.2%) remained on BI therapy 1 year after
the index date (Figure 4B and Table S1). The proportion of patients
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receiving premix insulin remained <10% post index in all countries, with
the exception of the UK, where 14.9% of patients had received premix
insulin at least once within 12 months after BI initiation. Proportions of
patients initiating rapid-acting insulin within the first year post index var-
ied relatively widely among countries, ranging from approximately 5% in
Spain to approximately 20% in Italy and the USA.
3.5 | Body weight
No clinically meaningful changes in mean body weight were
observed following BI initiation; mean increases ranged from
0.1 kg in Germany and the USA to 1.5 kg in France and the UK
(Table S2).
4 | DISCUSSION
In this study of patients with T2DM initiating BI in 5 European coun-
tries and the USA, a consistent pattern of short- and long-term sub-
optimal glycaemic control emerged. The majority of patients failed to
reach HbA1c target (≤7.0%) at 3 months or 2 years post index. In
addition, glycaemic control and hypoglycaemia incidence at 3 months
were associated with long-term glycaemic control and hypoglycaemia
incidence, respectively.
As seen in previous studies in populations initiating BI,13,18,19
these patients were characterized by elevated HbA1c levels at base-
line; a high proportion of patients initiated BI with HbA1c > 9.0%,
highlighting a disconnect between real-world clinical practice and
Country  OR 95% CI
Country  OR 95% CI
France  5.04 3.53–7.18
Germany  3.71 2.84–4.85
Italy  5.22 3.19–8.52
Spain  3.50 1.85–6.62
UK  5.51 3.73–8.13
USA  3.51 3.21–3.84
Overall  3.70 3.41–4.00
0.6 1 6 12
Odds ratio (95% CI)
A
France  7.84 3.40–18.06
Germany  6.72 2.92–15.44
Italy  4.69 1.76–12.47
Spain  4.58 1.27–16.48
UK  19.97 6.85–58.19
USA  5.30 4.22–6.66
Overall  5.71 4.67–6.99
0.6 1 6 60
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B
FIGURE 2 Odds ratios A, for risk of not achieving target HbA1c ≤7.0% after 24 months if target is not achieved in the first 3 months, and B,
for risk of hypoglycaemia after 24 months if hypoglycaemia is experienced in the first 3 months. CI, confidence interval; OR, odds ratio. Results
adjusted for A, pre-index HbA1c levels and B, pre-index hypoglycaemia experience. For the 3-month time point, the closest available HbA1c
value was to be used and must have been measured between 2 and 4 months after BI initiation. For other time points after the index date, the
HbA1c value nearest to that time point was to be used and the measurement should not have overlapped with that used at the 3-month time
point. Overall OR was derived from a meta-analysis of results from all 6 countries, using an inverse-variance weighted method
MAURICIO ET AL. 1159
recommendations in clinical guidelines, and indicating a delay in initi-
ating insulin far beyond the point of need. This is of critical concern
given the need for tight glycaemic control and/or appropriate
treatment intensification to reduce the risk of diabetes-related
complications,15,20–22 to help preserve β-cell function23,24 and to
achieve long-term glycaemic goals.25–27 As such, the success of
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BI-supported oral therapy is dependent on timely initiation during
the natural history of T2DM in the individual patient. In support of
this, across the 6 countries in this study, patients in Germany initiated
BI at the lowest HbA1c level, and had the highest proportion of
patients achieving HbA1c ≤7.0% post index. Given the large propor-
tion of the study population who did not reach glycaemic targets using
BI and OADs, considering addition of prandial coverage through pre-
mix or basal-bolus insulin regimens might have been a suitable option
for some patients.
The broader literature supports a widespread existence of clinical
or therapeutic inertia,13,28–33 with some patients in the UK experien-
cing more than 7 years of poor glycaemic control before initiating
insulin.13,32 Future research priorities should address how delays in
insulin therapy initiation and how barriers to effective titration could
be overcome.
A high proportion of patients in this analysis did not achieve the
HbA1c target of ≤7.0% in the 2 years following BI initiation, similar
to findings from other database studies performed in the UK and
Germany,34,35 and in the Study of Once-Daily Levemir (SOLVE), con-
ducted in 10 countries.36 In our study, many patients had comorbid
conditions and those from Europe had a median age >65 years; thus,
it is possible that relaxed HbA1c targets were set for these patients,
in line with current guidelines.3,37 For example, it may be appropriate
to set less stringent glycaemic goals in older adults with comorbid-
ities, who may have previously experienced hypoglycaemia or be at
increased risk of hypoglycaemia and more vulnerable to the adverse
effects associated with these events.8 However, data on individual
patient targets were not available in this retrospective study. It is
important to note that, although many patients do not reach recom-
mended HbA1c targets, they may still experience a clinical benefit
from the reduction they do achieve.38
Though HbA1c varied by country, failure to achieve a target of
≤7.0% by 3 months post BI initiation was associated consistently
with suboptimal long-term blood glucose control. Short-term failure
to achieve HbA1c target with BI alone may predict the need for early
treatment intensification, in line with ADA-EASD recommendations.1
Between-country differences in HbA1c values may reflect varying
approaches to diabetes management, target setting and treatment
intensification.
An unexpected finding was that experience of hypoglycaemia in
the pre-index period or in the first 3 months post index was not asso-
ciated with HbA1c target achievement. However, with only 5.1% of
patients experiencing ≥1 hypoglycaemic event during the first year
after BI initiation, the reported incidence of hypoglycaemia was lower
than that observed in randomised controlled trial settings 39; this may
be explained by the underreporting of such events in database stud-
ies (discussed below). The low incidence of hypoglycaemia may have
masked any potential association between experience of hypoglycae-
mia and failure to achieve glycaemic targets.
Given the established association between insulin use and
increased risk of hypoglycaemia, the incidence of hypoglycaemia was
expected to increase following BI initiation.40 This was observed in
Germany, Italy, Spain and the USA; however, there was a decline in
recorded hypoglycaemia in France and the UK during the 1-year
post-index period. The use of relaxed glycaemic targets in some
patients, and differences in patient education or concomitant medi-
cation usage may have affected hypoglycaemia incidence. A similar
observation was made during the SOLVE study, during which severe
hypoglycaemia rates declined after BI initiation, despite the fact that
the majority of patients continued to have HbA1c levels above tar-
get, indicating a general lack of aggressiveness in titration prac-
tices.36 Certain high-risk OADs, such as SUs, are known to increase
the incidence of hypoglycaemia compared with other agents, such
as metformin and DPP-4 inhibitors.1,41,42 In the SOLVE study,
patients who continued SUs after BI initiation experienced higher
rates of hypoglycaemia than those who discontinued this treat-
ment.43 In our study, use of concomitant medication varied by
country, which may reflect differing treatment practices; however,
the UK had the highest proportion of patients using SUs and under-
going further treatment intensification with prandial or rapid-acting
insulin in the post-index period. It is difficult to explain the decline
in hypoglycaemia after BI initiation in France and the UK as dosing
data were not available, although reporting bias may have played a
role. This merits further investigation, potentially with other data
sources.
Independent of baseline hypoglycaemia experience, hypoglycae-
mia during the first 3 months after BI initiation was associated con-
sistently with hypoglycaemia risk over the ensuing 3 to 24 months.
Our analysis also suggested that some comorbidities known to be
associated with high hypoglycaemic risk (eg, renal disease, congestive
heart failure) were predictive of post-index hypoglycaemia in some
countries. Broad strategies to address some of the unmet needs asso-
ciated with insulin therapy may include next-generation blood
glucose-lowering agents, both oral therapies and BIs.44 For example,
a BI that is able to control HbA1c without increasing hypoglycaemic
risk may help to overcome patient and physician fears surrounding
insulin initiation. Combining BIs with anti-hyperglycaemic drugs asso-
ciated with a low risk of hypoglycaemia, and introduction of GLP1-
RA to treatment regimens rather than prandial insulin, may further
reduce hypoglycaemic risk.45,46
A key study strength is that the results reflect real-life clinical
practice in a diverse range of countries, and there is currently a
regrettable paucity of such clinically relevant data in this setting. Data
were included from a large number of patients from multiple coun-
tries, allowing a substantial and representative cohort of the
European and US patient population to be analysed; indeed, the
results may be judiciously extrapolated to other countries.
As an observational study, this analysis is necessarily limited by
the information captured in patient records. Some findings, such as
between-country differences in comorbidity prevalence, particularly
renal disease, may be explained by reporting bias. The lower rates
observed in some countries may relate to differing definitions of renal
disease, and also to under-reporting of the condition. Evidence from
the European Society of Cardiology and the EASD suggests that
approximately 25% of people with T2DM have CKD (stage 3-4).47
However, other data indicate that CKD rates may be under-
reported,48 possibly because of lack of awareness and screening for
the condition.49 A study in the USA indicated that 54% of patients
with T2DM had CKD (stage 1-5), but this was diagnosed in only 12%
of cases.48
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Complications, particularly hypoglycaemia, may also have been
under-reported; it is of note that the true burden of hypoglycaemia in
this population is likely to be underestimated because only EMR-
captured episodes were analysed. Identification of hypoglycaemia
relied on accurate documentation, which may itself depend on
patient recall that can be subject to memory bias50; asymptomatic
events would not have been recorded unless they occurred during an
office visit. As discussed above, the incidence of hypoglycaemia is
likely to be influenced by the use of certain concomitant medications.
However, as medication usage was based on written prescriptions,
and treatment switching, adherence and persistence were not evalu-
ated, the incidence of hypoglycaemia according to concomitant medi-
cation should be interpreted with caution.
As might be expected from such a study, a proportion of the
total patient population would have been excluded because of the
lack of available data. However, we would expect the large sample of
patients included to be generally representative of the total popula-
tion, noting that there may have been a selection bias towards
patients who were more likely to undergo HbA1c testing and to com-
plete the test in a timely manner. In comparison to the SOLVE study
of patients initiating insulin (detemir) treatment, the patients in our
study were of a similar age and had a similar level of glycaemic con-
trol at baseline (including high numbers of patients with
HbA1c >9.0%), but had lower levels of micro- and macro-vascular
comorbidities.36 Not all patients were included at each post-index
time point, and patients may have received care from physicians who
did not contribute to the database. Individualized HbA1c targets
could not be captured and, thus, were not considered when deter-
mining glycaemic target achievement. Furthermore, insulin dosage
information was not available; therefore, we can only speculate that
potential inadequate titration may also have contributed to failure to
achieve HbA1c target.
The limitations of this retrospective analysis may, in part, be
overcome in future studies using a prospective design. Following on
from the current study, results from the ongoing, large, prospective
Diabetes Unmet Needs with basal insulin Evaluation (DUNE) study
may provide a more robust evaluation of glycaemic target achieve-
ment and hypoglycaemia incidence in patients initiating BI, and also
in BI users requiring treatment optimization.51
In conclusion, these results highlight hypoglycaemia incidence
and inadequate treatment responses in patients with T2DM initiating
BI within a diverse range of countries and healthcare systems. Many
patients had high HbA1c levels prior to BI initiation, indicating a delay
in treatment intensification. Despite the availability of multiple treat-
ment options, the majority of patients did not achieve target HbA1c
at 3 or 24 months. The study has implications for clinical practice, as
early failure to reach glycaemic targets or experience of a hypogly-
caemic episode was indicative of longer-term blood glucose control
and future hypoglycaemia risk, respectively.
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